Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report
Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164
Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects
Evaluation of BMS-986142, a Reversible Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: A Phase 2, Randomised, Double-blind, Dose-ranging, Placebo-controlled, Adaptive Design Study
Lancet Rheumatol 2023;5:e263–73 doi 10.1016/S2665-9913(23)00089-9
Investigators from a phase 2 study concluded that further investigation with BMS-986142 (a novel BTK) in people with RA is not necessary.
Secukinumab Improves Physical Function and Quality of Life and Inhibits Structural Damage in Patients with PsA with Sustained Remission or Low Disease Activity: Results From the 2-year Phase 3 FUTURE 5 Study
RMD Open 2023;9:e002939 doi 10.1136/rmdopen-2022-002939
Results from the 2-year phase 3 study FUTURE 5 show that the majority of patients with PsA who are treated with secukinumab were able to achieve sustained low disease activity or remission by week 104.
Incidence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
JAMA Netw Open. 2023;6(3):e233640 doi: 10.1001/jamanetworkopen.2023.3640
Retrospective cohort study results suggest that treatment with tofacitinib, and perhaps other JAK inhibitors, may provide a benefit in reducing the risk of developing RA-Interstitial Lung Disease (ILD).
Keywords:
Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study
Lancet Rheumatol 2023;5:200–207 doi https://doi.org/10.1016/S2665-9913(23)00034-6
Retrospective cohort study found 15 501 PsO patients in the TriNetX database during January 2014–June 2022 that were prescribed bDMARDS, of which 6.3% developed inflammatory arthritis. 3.5% of all patients in the study specifically developed PsA.
Sex Differences in the Efficacy, Safety and Persistence of Patients with Psoriatic Arthritis Treated with Tofacitinib: A Post Hoc Analysis of Phase 3 Trials and Long-Term Extension
RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718
Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients with Active Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523
TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.
Keywords:
Factors Associated with the Retention of Secukinumab in Patients with Axial Spondyloarthritis in Real-world Practice: Results from a Retrospective Study (FORSYA)
RMD Open. 2023 doi: 10.1136/rmdopen-2022-002802 Epub Ahead of Print
This study reported the overall retention of secukinumab in daily practice in the period following its approval in France was approximately 59% at 1 year in axSpA patients. The aim of this study was to determine whether OSI were predictive of secukinumab retention at 1 year.
Keywords:
Efficacy and Safety of Golimumab in Patients with Non-radiographic Axial Spondyloarthritis: A Withdrawal and Retreatment Study (GO-BACK)
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead112 Epub Ahead of Print
This study highlighted that continued treatment with Golimumab (GLM) QMT or GLM Q2MT was superior to placebo. The GO-BACK study was designed to evaluate the efficacy and safety of golimumab treatment withdrawal in adults with nr-axSpA who demonstrate inactive disease during a 10-month open label GLM run-in.
Keywords:
Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead089
These real-world data from PsABio on gender differences suggest that, at the start of biologic treatment, females have a worse clinical picture of PsA than males. In coming to these conclusions and others, this study sought to investigate effects of gender on disease characteristics and treatment impact in patients with PsA.